SEC Form 4 · accession 0001209191-17-052843
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
G Bradley Cole
Officer — COO
Period of report
Sep 12, 2017
Accepted (ET)
Sep 14, 2017 · 5:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 12, 2017 | M | 5,000 | $17.33 | A | 44,935 | D | |
| Common StockF2,F3,F4,F1 | Sep 12, 2017 | S | 5,000 | $31.8575 | D | 39,935 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5 | $17.33 | Sep 12, 2017 | M | 5,000 | D | — | Dec 4, 2018 | Common Stock | 0 | 30,000 | D |
Explanation of responses
- F1Includes an aggregate of 18,174 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F2These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on March 9, 2017.
- F3Represents weighted average sale price. Actual sale prices ranged from $31.66 to $32.06.
- F4Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F5The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.